Back to TWST Overview
NMS · Valuation Lab
TWST
Twist Bioscience Corporation
Last$115.01
Market cap7.2B
EV/EBITDA-53.6x
Intrinsic value
$24.67
MoS -366.2% · Overvalued
Assuming 15.0% FCF margin and 23.2% Y1–5 growth.
Upside to price
EV (DCF)1.5B
Terminal share45%
Expected IV$25.46
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 45% of EV
PV of stage FCFs824.9M
PV of terminal value663.7M
Enterprise value1.5B
Net cash / (debt)58.2M
Equity value1.5B
Intrinsic value / share$24.67
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 532M | 79.8M | 69.5M | 87.1% |
| Y2 | 655.4M | 98.3M | 74.6M | 75.8% |
| Y3 | 807.4M | 121.1M | 80M | 66.0% |
| Y4 | 994.8M | 149.2M | 85.8M | 57.5% |
| Y5 | 1.2B | 183.8M | 92.1M | 50.1% |
| Y6 | 1.4B | 205.2M | 89.5M | 43.6% |
| Y7 | 1.5B | 229M | 87M | 38.0% |
| Y8 | 1.7B | 255.5M | 84.5M | 33.1% |
| Y9 | 1.9B | 285.2M | 82.1M | 28.8% |
| Y10 | 2.1B | 318.2M | 79.8M | 25.1% |
| Terminal | — | — | 663.7M | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.